Research Keyword: rapid-acting antidepressants

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Read More »

New and emerging pharmacologic treatments for MDD

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »
Scroll to Top